Compare Palantir Technologies Inc (PLTR) vs TG Therapeutics Inc (TGTX) Price & Performance

Palantir (PLTR) trades at $198.78, up 2.44% today, showing strong momentum with nine consecutive earnings beats. The stock exhibits bullish technical signals with current price near pivot point resistance at $199. Fundamentally, revenue grew 56.2% to $4.48B in 2025 with net income margin expanding to 36.3%, though valuation metrics remain elevated with P/E of 169.9 and P/S of 83.02. Recent partnership with Armada for sovereign AI infrastructure highlights ongoing business development.

Outlook remains positive given accelerating AI adoption and strong execution, but premium valuation and technical overbought conditions warrant caution. Key risks include growth normalization and competitive pressures. Analyst consensus is bullish with 54% buy ratings and $191.69 price target, though current price exceeds consensus target.

TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.

The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.